Drug intelligence / Profile preview

AZ'3202

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous

Overview

AZ'3202 is an investigational small molecule BH3 mimetic that acts as a selective inhibitor of B-cell lymphoma-extra large (BCL-XL), an anti-apoptotic member of the BCL2 protein family. Developed by AstraZeneca, the compound is designed to trigger apoptosis in malignant cells that depend on BCL-XL for survival. In preclinical studies involving T-cell acute lymphoblastic leukemia (T-ALL), AZ'3202 has been evaluated for its cytotoxicity across various molecular subtypes and its potential synergy with other anti-leukemic agents. Its activity appears to be influenced by the specific molecular taxonomy of the leukemia, with varying sensitivity observed across different genetic subtypes.

Targets

BCL2L1 (B-cell lymphoma-extra large protein)

Beyond the preview

Go deeper on AZ'3202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZ'3202.

Explore the full profile